Abstracts tagged "Lupus nephritis"

Abstract Number: 0090 • ACR Convergence 2024
Parenchymal and Hematopoietic IFNγ Signaling Exhibits Dichotomous Effects in Murine Lupus
Minjung Kim¹, Anthony Marinov², Haylee Cosgrove³, Xiaoyan Gong³, Mark Shlomchik³ and Jeremy Tilstra³, ¹University of Illinois College of Medicine at Chicago, Chicago, IL, ²University of Pittsburgh, Homestead, PA, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Lupus nephritis is the most common life-threatening end-organ complication of SLE, and response rates to current interventions remain poor. Notably, PD-L1 and other interferon-responsive…
Abstract Number: 0650 • ACR Convergence 2024
Tubulointerstitial Inflammation Predicts Tubular Atrophy, Fibrosis, and Renal Function Loss in Lupus Nephritis
Yevgeniya Gartshteyn¹, Laura Geraldino², Shuwei Wang³, Vivette D'Agati¹ and Robert Winchester¹, ¹Columbia University Irving School of Medicine, New York, NY, ²Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, ³Rutgers New Jersey Medical School, Newark, NJ
Background/Purpose: Current classification criteria of lupus nephritis (LN) emphasize glomerular pathology, however tubular atrophy and interstitial fibrosis (TAIF) are better predictors of poor…
Abstract Number: 0905 • ACR Convergence 2024
High-Throughput Proteomic Profiling of Sera as a Non-Invasive Method for Identifying Lupus Nephritis Subtypes
Rufei Lu¹, Andrea Fava², Benjamin Jones³, Peter Izmirly⁴, Jennifer Anolik⁵, Chaim Putterman⁶, David Wofsy⁷, Matthias Kretzler⁸, Celine Berthier⁹, E. Steve Woodle¹⁰, Michael Weisman¹¹, Mariko Ishimori¹², The Accelerating medicines Partnership: RA/SLE Network¹³, Betty Diamond¹⁴, Jill Buyon¹⁵, Michelle Petri¹⁶, Richard Furie¹⁷, Judith James¹³ and Joel Guthridge¹³, ¹University of California San Francisco, San Bruno, CA, ²Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Oklahoma State University, Oklahoma City, OK, ⁴New York University Grossman School of Medicine, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Albert Einstein College of Medicine, Safed, Israel, ⁷University of California San Francisco, SF, CA, ⁸University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁹University of Michigan, Ann Arbor, MI, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, ¹¹Stanford University, Los Angeles, CA, ¹²Cedars-Sinai Health System, Los Angeles, CA, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁵NYU Grossman School of Medicine, New York, NY, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD, ¹⁷Northwell Health, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) treatment decisions are typically informed using histopathological classification based on the International Society of Nephrology/Renal Pathology Society (ISN/RPS) and NIH activity…
Abstract Number: 1546 • ACR Convergence 2024
Characteristics and Treatment Patterns of Patients with Lupus Nephritis: A Retrospective Claims Database Study in the USA
Anisha M. Patel¹, Carmen Ng¹, Lisa Lindsay¹, Zhiyu Xia², William F. Pendergraft III³ and Maria Dall'Era⁴, ¹Genentech, Inc., South San Francisco, ²Genentech, Inc., Sou, ³Genentech, Inc., Chapel Hill, NC, ⁴UCSF, Corte Madera, CA
Background/Purpose: Accounting for the integration of new immunosuppressive treatment options (belimumab and voclosporin) since 2021, we aimed to describe real-world treatment patterns in patients with…
Abstract Number: 2159 • ACR Convergence 2024
Reaching Those in Need: Understanding the Reach of a Digital Program for Lupus Self-Management Education
Katherine Carpenter¹, Melissa French², Sara Johnson³, Janet Johnson³, Ashley Holden⁴, Joy Buie¹, Melicent Miller¹ and Mary Crimmings¹, ¹Lupus Foundation of America, Washington, DC, ²Lupus Foundation of America, Alexandria, VA, ³ProChange Behavior Solutions, South Kingstown, RI, ⁴Lupus Foundation of America, Bossier City, LA

Background/Purpose: As part of a 5-year cooperative agreement with the Centers for Disease Control and Prevention, The Lupus Foundation of America (LFA) has implemented the…
Abstract Number: 2601 • ACR Convergence 2024
Platelets Specifically Interact with Remigrating Neutrophils and Promote Immunogenic Cellular Death in Systemic Lupus
Marie nansion¹, Eloi Schmauch², Pierre Vacher³, Jean Sibilia⁴, Nathan Broussaudier¹, Adeline Bruchon¹, Pierre Grenot¹, Anne-Sophie Korganow⁵, Thierry Martin⁵, Sophie Caillard⁶, Anna Duval⁶, Jacques-Eric Gottenberg⁷, Raphaël Carapito¹, Séiamak Bahram¹, Patrick Blanco⁸ and Marc Scherlinger⁹, ¹UMR_INSERM 1109, Strasbourg, France, ²Broad Institute of MIT and Harvard, Cambridge, MA, USA., Boston, MA, ³Inserm U1045, Bordeaux, France, ⁴Strasbourg University Hospital, National reference center for autoimmune disease, Rheumatology, Strasbourg, France, ⁵Strasbourg University Hospital, National reference center for autoimmune disease, Clinical Immunology, Strasbourg, France, ⁶Nephrology department, HUS, Strasbourg, France, ⁷Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ⁸UMR_CNRS 5164 Immunoconcept, BORDEAUX CEDEX, France, ⁹Strasbourg University Hospital; INSERM 1109, Strasbourg, France
Background/Purpose: In SLE, platelet activation (express P-selectin+) follows the disease activity, which plays a role in thrombosis as well as in inflammation (1). Neutrophils express high levels of PSGL-1,…
Abstract Number: 0091 • ACR Convergence 2024
Targeting Endothelial Dysfunction in Lupus Nephritis: Effect of Sepiapterin, a Drug That Restores Endothelial Nitric Oxide Synthase Function, in a Murine Model of Lupus Nephritis
Dayvia Russell¹, Sandra Mungaray², Soroush Moradi² and Jim Oates², ¹Ralph H. Johnson VA, Charleston, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis (LN) is characterized by chronic endothelial cell dysfunction (ECD), which occurs when endothelial nitric oxide synthase (eNOS) becomes uncoupled, producing harmful reactive…
Abstract Number: 0651 • ACR Convergence 2024
Renal Survival and Mortality in Patients with Proliferative and Membranous Lupus Nephritis
Jung-Min Shin¹, Jiyoung Lee², Hye-Soon Lee³, Sang-Cheol Bae³ and So-Young Bang³, ¹Department of Rheumatology, Nowon Eulji Medical Center, Seoul, Republic of Korea, ²Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Lupus nephritis (LN) affects approximately 50% of patients and is a major determinant in the survival and prognosis of patients with systemic lupus erythematosus…
Abstract Number: 1040 • ACR Convergence 2024
Clinic Personnel Perceptions Were Favorable for the Implementation of a Patient Decision-Aid for a Diverse Systemic Lupus Erythematosus Population: A Study in 15 U.S. Rheumatology Clinics
Jasvinder Singh¹, Larry Hearld², Walter Chatham³, Sonali Narain⁴, Narender Annapureddy⁵, Diane Kamen⁶, Kimberly Trotter⁷, vikas Majithia⁸, Cathy Lee Ching⁹, Zineb Aouhab¹⁰, Swamy Venuturupalli¹¹, Daniel Wallace¹², rosalind Ramsey-Goldman¹³, Alfred Kim¹⁴, Maureen McMahon¹⁵, S. Sam Lim¹⁶, Kalpana Bhairavarasu¹⁷, Alexa Meara¹⁸ and Kenneth Kalunian¹⁹, ¹Baylor College of Medicine, Birmingham, AL, ²University of Alabama at Birmingham (UAB), Birmingham, AL, ³University of Nevada, Las Vegas, Las Vegas, NV, ⁴Northwell Health, Great Neck, NY, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶Medical University of South Carolina, Charleston, SC, ⁷University of Chicago, Chicago, IL, ⁸University of Missisippi Medical Center (UMC), Jackson, MS, ⁹UMMC, Jackson, MS, ¹⁰Loyola University Medical Center, Oak Brook, IL, ¹¹Attune Health, Beverly Hills, CA, ¹²Cedars Sinai Medical Center, Studio City, CA, ¹³Northwestern University, Chicago, IL, ¹⁴Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹⁵UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁶Emory University, Atlanta, GA, ¹⁷Baylor College of Medicine, Sugar Land, TX, ¹⁸The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹⁹University of California San Diego, La Jolla, CA
Background/Purpose: To understand clinic personnel feedback regarding the implementation of a self-administered patient decision-aid (PtDA) for lupus in regular, outpatient rheumatology clinics.Methods: We provided self-administered…
Abstract Number: 1642 • ACR Convergence 2024
A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis
Andrea Fava¹, Andrew Concoff², Tyler O'Malley³, Sepehr Taghavi⁴, Touba Warsi⁴, Sudha Kumar⁴, Christine Schleif⁴ and Michelle Petri⁵, ¹Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Exagen, Inc., Los Angeles, CA, ³Exagen, Vista, CA, ⁴Exagen, Carlsbad, CA, ⁵Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Achieving an NIH Activity Index of < 2 upon treatment is associated with less LN flare and thus better long-term kidney survival. Here, we…
Abstract Number: 2371 • ACR Convergence 2024
The Role of Intracytoplasmic Toll- Like Receptors (TLR) and MyD88 in B Cell Subsets as Renal Response Predictors in Patients with Lupus Nephritis
Fabiola Cassiano-Quezada¹, José Jiram Torres-Ruiz², Jennifer Balderas Miranda³, José Luis Maravillas-Montero⁴, Karina Santana-de Anda², Beatriz Alcalá-Carmona⁵, Nancy R Mejía-Domínguez⁵, Yatzil Reyna-Juárez⁵, María José Ostos-prado⁵, Guillermo Juarez-Vega⁴ and Diana Gomez-martin⁶, ¹Department of Internal Medicine. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ²Departament of Immunology and Rheumatology. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ³Universidad Nacional Autónoma de México, Ciudad de México, Mexico, ⁴Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ⁶INCMNSZ, Mexico City, Federal District, Mexico
Background/Purpose: Recently, a gain of-function mutation within TLR7 was identified to induce SLE in a murine model and increased the survival of activated B lymphocytes,…
Abstract Number: 2658 • ACR Convergence 2024
Hypovitaminosis D in Lupus Nephitis
Alicia Yupe¹, Emma Puron Gonzalez², Esteban Salatino³, Jessica Santana⁴, Montserrat Ochoa⁴, Rosa Elena Cervantes-Ramirez⁵, Eli Marisol Saldaña⁶, gabriel Calderon⁷, Brissia Ceniceros⁸, Ulices de la Cruz⁹, Monica Meza¹⁰ and Sergio Cerpa Cruz⁶, ¹Facultad de Ciencias Médicas, Universidad de San Carlos de Guatemala., Guatemala, Guatemala, ²UDEM/ITESM, San Pedro Garza Garcia, Mexico, ³Faculty of Medical Sciences, Universidad de San Carlos de Guatemala., Guatemala, GU, ⁴Hospital Civil "Fray Antonio Alcalde", Guadalajara, Mexico, ⁵Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico, Distrito Federal, Mexico, ⁶Hospital Civil de Guadalajara, Guadalajara, Mexico, ⁷Hospital Civil de Guadalajara, Monterrey, Mexico, ⁸Hospital Civil de Guadalajara, Torreón, Coahuila de Zaragoza, Mexico, ⁹Hospital Civil "Fray Antonio Alcalde", Guadalajara, ¹⁰Centro Universitario de Ciencias de la SAlud, Guadalajara
Background/Purpose: The prevalence of vitamin D deficiency is higher in patients with systemic lupus erythematosus (SLE) compared to the healthy population, and recent studies have…
Abstract Number: 0168 • ACR Convergence 2024
Real-world Glucocorticoid Prescription Patterns in Patients with Lupus Nephritis: A Retrospective Study Using a Healthcare Insurance Claims Database
Tatsuya Atsumi¹, Hironari Hanaoka², Nobuo Nishijima³, Kohji Murakami⁴, Mariko Nio³, Tsutomu Urakawa³, Takaaki Fujimura³ and Hiroki Hayashi⁵, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, ⁴Nippon Shinyaku Co., Ltd., Tokyo, Japan, ⁵Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
Background/Purpose: Lupus nephritis (LN) is one of the most frequent organ manifestations of systemic lupus erythematosus (SLE), affecting morbidity and mortality in SLE. LN is…
Abstract Number: 0652 • ACR Convergence 2024
Analysis of Relapses in a Single Center Cohort of Patients with Lupus Nephritis
Gamze Kemec¹, Sibel Varelci², Erdem Gurel², Isın Kılıcaslan³, Yasemın özlük³, Yasemın Yalcınkaya⁴, Ahmet Gul⁵, Murat Inanc⁶ and bahar Artım Esen⁴, ¹Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine Istanbul Faculty of Medicine, Istanbul, Turkey, ³Department of Pathology Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Division of Rheumatology, Department of Internal Medicine, Istanbul, Turkey, ⁵Division of Rheumatology, Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey, ⁶Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Relapses are correlated with increased hospitalizations, poor renal outcomes, morbidity and mortality. We aim to investigate the incidence, predictive factors and outcomes related to…
Abstract Number: 1068 • ACR Convergence 2024
Improving Health Numeracy Literacy in Pediatric Patients with SLE
Nicole Salach¹, Sarah Rogal¹, Jessica Simpson¹, Sangeeta Sule², Abigail Bosk³ and Catherine Park¹, ¹Children's National Hospital, Washington DC, DC, ²Children's National Hospital, Washington, DC, ³Children's National Hospital, Bethesda, DC
Background/Purpose: Health literacy is key to better patient outcomes. One aspect of health literacy that warrants additional investigation in patients who have systemic lupus erythematosus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.